Intellia Therapeutics (NASDAQ:NTLA) Raised to "Outperform" at Wolfe Research

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) was upgraded by stock analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating in a research report issued on Monday, MarketBeat Ratings reports. The brokerage currently has a $21.00 price target on the stock. Wolfe Research's target price would suggest a potential upside of 152.71% from the stock's previous close.

Several other analysts have also weighed in on NTLA. Wells Fargo & Company decreased their target price on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a research note on Monday, March 3rd. HC Wainwright started coverage on Intellia Therapeutics in a research report on Wednesday, March 5th. They set a "buy" rating and a $30.00 target price for the company. Chardan Capital lowered their price target on Intellia Therapeutics from $91.00 to $68.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. Finally, Citigroup boosted their target price on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the company a "neutral" rating in a research note on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $36.68.

Intellia Therapeutics Trading Up 1.6 %

NTLA stock traded up $0.13 during midday trading on Monday, hitting $8.31. The stock had a trading volume of 1,944,775 shares, compared to its average volume of 2,380,492. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $28.18. The stock has a 50-day simple moving average of $8.66 and a 200 day simple moving average of $11.85. The firm has a market capitalization of $860.23 million, a price-to-earnings ratio of -1.53 and a beta of 2.23.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors have recently modified their holdings of the stock. Hennion & Walsh Asset Management Inc. grew its holdings in Intellia Therapeutics by 125.2% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company's stock valued at $1,411,000 after purchasing an additional 67,276 shares during the period. Avanza Fonder AB bought a new position in Intellia Therapeutics during the fourth quarter worth about $421,000. Barclays PLC increased its holdings in shares of Intellia Therapeutics by 17.7% in the third quarter. Barclays PLC now owns 292,795 shares of the company's stock worth $6,017,000 after acquiring an additional 44,022 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Intellia Therapeutics by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company's stock valued at $48,164,000 after purchasing an additional 49,367 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in shares of Intellia Therapeutics by 10.3% in the 3rd quarter. Franklin Resources Inc. now owns 16,405 shares of the company's stock valued at $320,000 after purchasing an additional 1,538 shares during the period. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.